ProGen is a clinical-stage biotechnology company pioneering next-generation long-acting, multi-specific fusion protein therapeutics designed to improve patients’ quality of life.

Built on its proprietary NTIG® platform, ProGen develops long-acting biologic medicines that reduce treatment burden, improve dosing convenience, and enable more durable therapeutic benefit.

By engineering multi-specific fusion proteins, ProGen aims to achieve a better balance of efficacy, safety, and tolerability beyond conventional single-target therapies. ProGen’s platform is being advanced across metabolic diseases, immune-related disorders, and cancer through clinical development and global strategic partnerships.